Abstract: The present invention relates to a stabilized external preparation comprising thymosin beta 4 (T?4) as an active ingredient. More specifically, the present invention relates to a therapeutically effective external preparation with improved stability and biological activity of T?4. The preparation according to the present invention provides T?4 in a stable state by maintaining the biological activity of T?4 and minimizing the generation of T?4 sulfoxide through oxidization reactions and multimers through aggregation.

Abstract: A composition containing thymosin beta-4, an isoform of thymosin beta-4, an analogue thereof, or a derivative of thymosin beta-4 as an active ingredient and its use in promoting goblet cell proliferation and/or increasing mucin secretion are disclosed. The composition increases the expression of Muc5AC, Muc1, Muc4, and Muc16 and, thus, is considered to have an excellent effect on goblet cell or mucin-related diseases.

Abstract: The present invention relates to a method for manufacturing an ophthalmic preparation comprising thymosin ?4. According to the inventive method, the manufacture of an ophthalmic preparation comprising thymosin ?4 is carried out in the presence of an inert gas, thus the contact of thymosin ?4 with oxygen is blocked and the oxidation of thymosin ?4 can be prevented and the pharmacological activity of thymosin ?4 maintains for long-term period. Therefore, the ophthalmic preparation prepared by the inventive method can maintain the pharmacological activity of thymosin ?4 in a stable state for a long time.

Abstract: The present invention relates to a therapeutic agent for ophthalmic disease containing thymosin beta 4. The present invention is more effective in reducing xerophthalmia than an ophthalmic solution containing cyclosporine A, is less irritant to eyes than conventional ophthalmic solutions and is physiochemically safe.

Abstract: The present invention relates to a stabilized external preparation comprising thymosin beta 4 (T?4) as an active ingredient. More specifically, the present invention relates to a therapeutically effective external preparation with improved stability and biological activity of T?4. The preparation according to the present invention provides T?4 in a stable state by maintaining the biological activity of T?4 and minimizing the generation of T?4 sulfoxide through oxidization reactions and multimers through aggregation.

Abstract: The present invention relates to a method for manufacturing an ophthalmic preparation comprising thymosin ?4. According to the inventive method, the manufacture of an ophthalmic preparation comprising thymosin ?4 is carried out in the presence of an inert gas, thus the contact of thymosin ?4 with oxygen is blocked and the oxidation of thymosin ?4 can be prevented and the pharmacological activity of thymosin ?4 maintains for long-term period. Therefore, the ophthalmic preparation prepared by the inventive method can maintain the pharmacological activity of thymosin ?4 in a stable state for a long time.

Abstract: The present invention relates to a composition for the treatment or prevention of a corneal injury, which comprises thymosin ?4, and citric acid or its salt as active ingredients. The composition may further comprise at least one organic acid selected from acetic acid, ascorbic acid or salts thereof. The composition can maintain or increase the activity of thymosin ?4 conventionally used to effectively treat wounds on the cornea, and thus, is useful as an ophthalmic formulation for treating the corneal injury.

Abstract: The present invention relates to a therapeutic agent for ophthalmic disease containing thymosin beta 4. The present invention is more effective in reducing xerophthalmia than an ophthalmic solution containing cyclosporine A, is less irritant to eyes than conventional ophthalmic solutions and is physiochemically safe.

Abstract: The present invention relates to a composition for the treatment or prevention of a corneal injury, which comprises thymosin ?4, and citric acid or its salt as active ingredients. The composition may further comprise at least one organic acid selected from acetic acid, ascorbic acid or salts thereof. The composition can maintain or increase the activity of thymosin ?4 conventionally used to effectively treat wounds on the cornea, and thus, is useful as an ophthalmic formulation for treating the corneal injury.